Nutrition impact symptoms as prognostic indicators in gastric cancer: the role of quality of life and survival outcomes
- PMID: 40597891
- PMCID: PMC12211481
- DOI: 10.1186/s12885-025-14421-4
Nutrition impact symptoms as prognostic indicators in gastric cancer: the role of quality of life and survival outcomes
Abstract
Background: Nutrition impact symptoms (NIS) are common among cancer patients and influence prognosis. This study aimed to investigate the prognostic significance of NIS in gastric cancer patients using data from the Investigation on Nutrition Status and Clinical Outcome of Common Cancers (INSCOC) database.
Methods: We conducted a retrospective cohort study using data from 2,673 adult patients with confirmed gastric cancer enrolled in the INSCOC database between January 2013 to February 2020. NIS, including appetite loss, vomiting, dysphagia, and early satiety, were assessed using the Patient-Generated Subjective Global Assessment (PG-SGA). Overall survival (OS) was the primary outcome, while quality of life (QoL) was the secondary outcome. Statistical analyses included Kaplan-Meier survival analysis, Cox proportional hazards regression, and propensity score matching (PSM) to reduce confounding.
Results: Patients with NIS had significantly worse OS compared to those without (median OS: 74.1 vs. 81.3 months, p < 0.001). In multivariate analysis, NIS was an independent predictor of mortality (HR: 1.28, 95% CI: 1.11-1.48, p = 0.001). Vomiting and dysphagia were particularly associated with increased mortality (HR: 1.22, p = 0.038 and HR: 1.80, p < 0.001, respectively). Interaction analysis revealed that the prognostic impact of NIS was influenced by chemotherapy (P for interaction = 0.002). NIS was also strongly associated with severe malnutrition. Sensitivity analysis confirmed the robustness of these findings, even after excluding short-term mortalities within 180 days.
Conclusions: NIS are significant independent predictors of poor prognosis in gastric cancer patients, contributing to malnutrition and reduced survival. These findings highlight the importance of early symptom recognition and nutritional intervention to potentially improve outcomes for gastric cancer patients.
Trial registration: https://www.chictr.org.cn/showproj.html?proj=31813 , identifier ChiCTR1800020329.
Keywords: Gastric cancer; Malnutrition; Nutrition impact symptoms (NIS); Prognosis.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Ethics approval and consent to participate: This study was approved by the Ethics Committee of Beijing Shijitan Hospital and was registered in the Chinese Clinical Trial Registry (ChiCTR) under registration number ChiCTR1800020329. Due to the retrospective nature of the study, the requirement for informed consent was waived by the ethics committee. Consent for publication: All authors have read and approved the final manuscript and consent to its publication. Competing interests: The authors declare no competing interests.
Figures
Similar articles
-
Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.Cochrane Database Syst Rev. 2022 Sep 26;9(9):CD015048. doi: 10.1002/14651858.CD015048.pub2. Cochrane Database Syst Rev. 2022. PMID: 36161421 Free PMC article.
-
Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. doi: 10.3310/hta10340. Health Technol Assess. 2006. PMID: 16959170
-
Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant neoplasms, overall and progression-free survival: individual participant data analysis.Cochrane Database Syst Rev. 2017 Sep 13;9(9):CD008814. doi: 10.1002/14651858.CD008814.pub2. Cochrane Database Syst Rev. 2017. PMID: 28901021 Free PMC article.
-
A Comprehensive Analysis of the Association Between the EORTC QLQ-C30 Questionnaire and Cachexia in Patients With Gastric Cancer.J Cachexia Sarcopenia Muscle. 2025 Jun;16(3):e13859. doi: 10.1002/jcsm.13859. J Cachexia Sarcopenia Muscle. 2025. PMID: 40504106 Free PMC article.
-
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.Health Technol Assess. 2001;5(28):1-110. doi: 10.3310/hta5280. Health Technol Assess. 2001. PMID: 11701100
References
-
- Sung H, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. Cancer J Clin. 2021;71:209–49. 10.3322/caac.21660. - PubMed
-
- Chia NY, Tan P. Molecular classification of gastric cancer. Ann Oncol. 2016;27:763–9. 10.1093/annonc/mdw040. - PubMed
-
- Schütte K, Schulz C, Middelberg-Bisping K. Impact of gastric cancer treatment on quality of life of patients. Best Pract Res Clin Gastroenterol. 2021;50–51:101727. 10.1016/j.bpg.2021.101727. - PubMed
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous